IRCMS International Research Center for Medical Sciences

Research

Tomas Hanke
Ph.D.
Distinguished Professor

ACHIEVEMENT

Capucci S, Wee EG, Schiffner T, Labranche C, Klasse PJ, Cupo A, Dodd J, Sattentau Q, Dean H, Montefiori D, Sanders RW, Moore JP and Hanke T. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimmers. PLoS ONE 12: e0181886 (2017). https://doi.org/10.1371/journal. pone.0181886.

Hancock G, Morón-López S, Carmen Puertas M, Giannoulatou E, Rose A, Salgado M, Hayton E-J, Morgan C, Angus B, Chen F, Yang H, Martinez-Picado J, Hanke T and Dorrell L. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc 20:21171 (2017).

Borthwick N, Lin Z, Akahoshi T, Llano A, Silva-Arrieta S, Ahmed T, Dorrell L, Brander C, Murakoshi H, Takiguchi M and Hanke T. Novel subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS ONE  12:e0176418 (2017) doi: 10.1371/journal.pone.0176418. eCollection 2017.

Johnson LA, Banerji S, Lawrance W, Gileadi U, Prota G, Holder KA, Roshorm YM, Hanke T, Cerundolo V, Gale NW, Jackson DG. Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nat Immunol 18:762-770 (2017). doi: 10.1038/ni.3750.

Wee EG, Ondondo B, Berglund P, Archer J, McMichael AJ, Baltimore D, ter Meulen JH and Hanke T. HIV-1 conserved mosaics delivered by regimens with integration-deficient, DC-targeting lentivirus induce robust T cells. Mol Ther 25:494-503 (2017) doi: 10.1016/j.ymthe.2016.12.004

Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, Kopycinski JT, Hayes P, Borthwick NJ, Ashraf A, Dally L, Barin B, Tillander A, Gilmour J, De Bont J, Crook A, Hannaman D, Cox JH, Anzala O, Fast PE, Reilly M, Chinyenze K, Jaoko W, Hanke T and the HIV-CORE 004 study group. Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. Mol Ther Methods Clin Dev 3:16061 (2016). doi: 10.1038/mtm.2016.61

Jönsson P, Southcombe JH, Santos AM, Huo J, Fernandes RA, McColl J, Lever M, Evans EJ, Hudson A, Chang VT, Hanke T, Godkin A, Dunne PD, Horrocks MH, Palayret M, Screaton GR, Petersen J, Rossjohn J, Fugger L, Dushek O, Xu XN, Davis SJ and Klenerman D Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. PNAS. 133:5682-5687 (2016). doi: 10.1073/pnas.1513918113

Abdul-Jawad S, Ondondo B, van Hateren A, Gardner A, Elliott T, Korber B and Hanke T. Increased valency of conserved-mosaic vaccines enhances the breadth and depth of epitope recognition. Mol Ther. 24:375-384 (2016) doi: 10.1038/mt.2015.210.

Ondondo B, Murakoshi H, Clutton G, Sultan Abdul-Jawad S, Oka S, McMichael AJ, Takiguchi M, Korber B and Hanke T. Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection. Mol Ther. 24:832-842 (2016) doi: 10.1038/mt.2016.3.

Ternette N, Yang H, Partridge T, Llano A, Cedeño S, Fischer R, Charles P, Dudek NL, Purcell AW, Borrow P, Mothe B, Crespo M, Dorrell L, Brander C, Kessler BM and Hanke T. Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. Eur J Immunol 46:60-69 (2016) doi: 10.1002/eji.201545890.

Mothe M, Llano A, Rosati M, Olvera A, Hu X, Kulkarni V, Valentin A, Alicea C, Sardesai NY, Rocafort M, Crespo M, Carrillo J, Marco A, Mullins JI, Dorrell L, Hanke T, Clotet B, Pavlakis GN, Felber BK and Brander C. A Human Immune Data-Informed Vaccine Concept Elicits Strong and Broad T-cell Specificities Associated with HIV-1 Control in Mice and Macaques. J Translation Med 13:60 (2015). doi:10.1186/s12967-015-0392-5

Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, Payne TL, Berrong M, Ferrari G, Chopera D, Hanke T, Mothe B, Brander C, McElrath MJ, McMichael A, Goonetilleke N, Tomaras G, Frahm N, Dorrell L. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog 11(2) e1004658 (2015). doi:10.137/journal.ppat.1004658

Clutton G, Carpov A, Parks CL, Dean HJ, Montefiori DC and Hanke T. Optimizing parallel induction of HIV-1-specific antibody and T-cell responses by multicomponent subunit vaccines. AIDS 28: 2495-2504 (2014).

Njuguna IN, Ambler G, Reilly M, Ondondo B, Kanyugo M, Lohman-Payne B, Gichuhi C, Borthwick N, Black A, Mehedi S-R, Maleche-Obimbo E, Chohan B, John-Stewart GC, Jaoko W and Hanke T. PedVacc 002: A phase I randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-infected mothers in Nairobi. Vaccine 32: 5801-5808 (2014) doi: 10.1016/j.vaccine.2014.08.034.

Hanke T. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin. Biol. Ther. 14: 601-616 (2014).

Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ibrahimsa U, Hayton E-J, Black A, Bridgeman A, Rosario M, Hill AVS, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L and Hanke T. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22: 464-475 (2014) doi: 10.1038/mt.2013.248.

Njuguna I, Reilly M, Jaoko W, Gichuhi C, Ambler G, Maleche-Obimbo E, Lohman-Payne B, Hanke T and John-Stewart G. Infant neutropenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of HIV. Retrovirology 6: 1-5 (2014).

Afolabi MO, Ndure J, Drammeh A, Darboe F, Mehedi S-R, Borthwick-N, Rowland-Jones S, Black A, Hanke T and Flanagan KL. Phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants. PLoS ONE 8: e78289 (2013).

Roshorm Y, Cottingham M, Potash M-J, Volsky DJ and Hanke T. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens protect against chimeric HIV-1 challenge. Eur J Immunol: 42: 1-13 (2012).

Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mvula A, Bridgeman A, Colloca S, Monefiori D, McMichael AJ, Nicosia A, Drijfhout JW, Melief CJ, and Hanke T. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV in macaques. AIDS 26: 275-284 (2012).

Im E-J, Hong JP, Roshorm Y, Bridgeman A, Létourneau S, Liljeström P, Potash MJ, Volsky DJ, McMichael AJ and Hanke T. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenge. PLoS Pathog 7: e1002041 (2011).

Létourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ and Hanke T. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2:e984 (2007).

McMichael AJ,  and Hanke T. HIV vaccines 1983-2003. Nat Med 9, 874-880 (2003).